Metrics to compare | S2BP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipS2BPPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 3.0x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 1.5x | 2.6x | |
Price / LTM Sales | 0.0x | 0.8x | 3.2x | |
Upside (Analyst Target) | 0.0% | 20.4% | 49.5% | |
Fair Value Upside | Unlock | 10.0% | 7.1% | Unlock |
Syn2bio S.A., a biotechnology company, engages in the research and commercialization of Cardiac Marker, a radiopharmaceutical for diagnostic testing of heart disease in the field of myocardial perfusion. The company’s flagship project is the cardiotracer project, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. Additionally, it operates The Centre for Research on New Compounds, a unit engaged in the search for new pharmaceutical compounds and their further study, registration, and market launch as a medicinal product. Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.